RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.

ABSTRACT:

Background

This exploratory single-arm phase II study evaluated the efficacy and safety of RRx-001 followed by reintroduction of platinum plus etoposide in patients with previously treated small-cell lung cancer (SCLC).

Methods

Patients were treated with RRx-001 4 mg IV on day 1 of each week of a 21-day cycle followed at progression by re-challenge with etoposide 80-100 IV mg/m² on days 1, 2 and 3 and cisplatin 60-80 mg/m² IV on day 1 or carboplatin AUC 5-6 IV on day 1, every 21 days. The primary end points were overall survival (OS) and overall response rate to platinum regimen.

Results

Twenty-six patients were enroled and received at least one dose of RRx-001. The median number of prior lines of therapy was 2 (range 1-9) and 19 (73.1%) patients

SUBMITTER: Morgensztern D 

PROVIDER: S-EPMC6738071 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature